On Monday, the Veteran's Administration announced it would cover a new FDA-approved treatment for Alzheimer's disease. The decision came as a surprise because just a few weeks ago the Centers for Medicare & Medicaid Services (CMS) refused to expand coverage of the drug. The apparent conflict between agencies sends mixed signals on a topic requiring the utmost clarity. Solving Alzheimer's is a top priority for the Biden Administration. It must embrace policies that provide broad-based access to the best possible care and foster innovation.
Read Full Article »
